Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00534729
First received: September 21, 2007
Last updated: January 4, 2016
Last verified: January 2016
  Purpose
Organ Preservation: Weekly Carboplatin & Taxol w/concurrent RT for locally advanced laryngeal & Hypopharyngeal CA

Condition Intervention
Laryngeal Neoplasms
Hypopharyngeal Neoplasms
Drug: Weekly Carboplatin & Taxol w/concurrent RT

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • safety [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 200
Study Start Date: September 2007
Study Completion Date: September 2015
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Weekly Carboplatin & Taxol w/concurrent RT
    Chemotherapy
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with locally advanced laryngeal & Hypopharyngeal CA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00534729

Locations
Saudi Arabia
KFSH&RC
Riyadh, Saudi Arabia, 1211
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Nasser Al-Rajhi, MD KFSH&RC
  More Information

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT00534729     History of Changes
Other Study ID Numbers: RAC#0971-024 
Study First Received: September 21, 2007
Last Updated: January 4, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by King Faisal Specialist Hospital & Research Center:
Organ Preservation
Carboplatin
Taxol
RT
laryngeal & Hypopharyngeal CA
Locally advanced laryngeal & Hypopharyngeal CA

Additional relevant MeSH terms:
Neoplasms
Laryngeal Neoplasms
Hypopharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Laryngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Otorhinolaryngologic Diseases
Pharyngeal Neoplasms
Pharyngeal Diseases
Stomatognathic Diseases
Carboplatin
Paclitaxel
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on December 02, 2016